R & D- medical: biomedical (basic research)
Ended Awarded Last action
- Contract number
- 75N91018F00003
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Temple University-Of The Commonwealth System Of Higher Education
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $884,185
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $884,185.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19111, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | -$5,918 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $343,400 | |
| Original award | $546,703 |
About this award
The Institute For Cancer Research, a non-profit subsidiary of Temple University, has been awarded a $884,185.34 firm fixed price delivery order against the National Cancer Institute's PREVENT Cancer Program multiple award indefinite delivery contract vehicle. This delivery order focuses on continued evaluation of candidate chemopreventive and immunopreventive regimens in support of the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS through January 2024. The National Cancer Institute PREVENT Program aims to support preclinical drug development for cancer prevention through research services involving preclinical efficacy testing and biomarker analysis. No set-aside designation was specified for this award made by the Department of Health and Human Services' National Institutes of Health National Cancer Institute.
Quick answers
Who was awarded contract 75N91018F00003?
75N91018F00003 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on July 25, 2018.
How much is contract 75N91018F00003 worth?
The government has obligated $884,185 on 75N91018F00003.
Is contract 75N91018F00003 an order under another contract?
Yes. 75N91018F00003 is a delivery order under HHSN261201500032I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract 75N91018F00003 competed?
The extent of competition for 75N91018F00003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award